EP4426307
Ný lyfjasamsetning til gjafar um munn og lyfjagjafaráætlun til meðferðar á ágengum trefjandi millivefslungnasjúkdómum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
8.12.2022EP published:
2.7.2025EP application number:
22835249.8
EP translation filed:
27.8.2025Grant published:
15.9.2025EPO information:
European Patent Register
Max expiry date:
7.12.2042Expiry date:
7.12.2026Next due date:
31.12.2026
Title in English:
NEW ORAL PHARMACEUTICAL COMPOSITION AND DOSE REGIMEN FOR THE THERAPY OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASESLanguage of the patent:
English
Timeline
Today
8.12.2022EP application
2.7.2025EP Publication
27.8.2025Translation submitted
15.9.2025Registration published
7.12.2026Expires
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, 55216 Ingelheim am Rhein, DE
Inventor
Name:
HESSLINGER, ChristianAddress:
55216 Ingelheim am Rhein, DE
Name:
BAUER, VerenaAddress:
55216 Ingelheim am Rhein, DE
Name:
BOSSERT, Sebastian MartinAddress:
55216 Ingelheim am Rhein, DE
Name:
NICKOLAUS, PeterAddress:
55216 Ingelheim am Rhein, DE
Name:
KOBER, SusanAddress:
55216 Ingelheim am Rhein, DE
Name:
LIU, YiAddress:
Ridgefiled, Connecticut 06877-0368, US
Name:
SARNO, MariaAddress:
55216 Ingelheim am Rhein, DE
Name:
VOSS, FlorianAddress:
55216 Ingelheim am Rhein, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202163287642 PDate:
9.12.2021Country:
US
Number:
21218202Date:
29.12.2021Country:
EP
Number:
22177750Date:
8.6.2022Country:
EP
Classification
Categories:
A61K 31/519, A61P 11/00
Annual fees
Number
Paid
Expires
Payer
Number: 4
Paid: 11.12.2025
Expires: 7.12.2026
Payer: G.H. Sigurgeirsson ehf.